We obtained monoclonal antibodies against N1,N12-diacetylspermine (DiAcSpm) and N1,N8-diacetylspermidine (DiAcSpd), and developed two systems of competitive ELISA that utilize the antibodies and a common enzyme-labeled antigen to measure these di acetylpolyamines.
In the decades since Russell et al. (1, 2) reported that the amount of polyamines excreted in urine is higher in pa tients with cancer than in healthy persons, it has become recognized that the total amount as well as the amounts of individual free and monoacetylated polyamines in urine can not alone serve as a conclusive measure for the diagno sis of cancer because of fluctuations among individuals and the occurrence of many false negative as well as false posi tive cases (3-6).
Using high performance liquid chromatography (HPLC), we demonstrated that N1,N8-diacetylspermidine (DiAcSpd) and N1,N12-diacetylspermine (DiAcSpm) are present in healthy human urine with small fluctuations among indi viduals (7), and that these two diacetylpolyamines, rather than the total or other individual polyamine species, might be useful as novel tumor markers serving as diagnostic and prognostic indicators of cancers (8, 9). While analysis by HPLC is sensitive and versatile, it is time-consuming and inconvenient for handling large numbers of samples. We, therefore, developed an enzyme-linked immunosorbent as say (ELISA) procedure for the determination of DiAcSpd (10) and DiAcSpm (11) using affinity-purified polyclonal rabbit antibodies. In this article, we describe the development of two sys tems of competitive ELISA using monoclonal antibodies, each intended for one of the two diacetylpolyamines. These systems both feature the use of a common horseradish per oxidase-labeled antigen. The antigen showed comparable affinities for the two antibodies which enabled us to con struct ELISA systems with comparable sensitivities for DiAcSpm and DiAcSpd. The use of a common antigen sig nificantly simplifies the overall design of the ELISA. Polyamine-Protein Conjugates N-Acetylspermine (Ac Spm) and N8-acetylspermidine (Ng-AcSpd) were conjugated separately to BSA using disuccinimidyl suberate as a cross linker according to the manufacturer's instructions to serve as antigens for raising anti-DiAcSpm and anti-DiAcSpd antibodies, respectively. AcSpm and N8-AcSpd were also conjugated to MSA in the same way to serve as antigens for screening hybridomas and used to coat the bottom of micro titer plate wells. AcSpm was conjugated to HRP (AcSpm HRP) according to the procedure described by Nakane, in which a Schiff base formed by the reaction between the pri mary amino group of AcSpm and the aldehyde group of oxi dized HRP is reduced with sodium borohydride (12) and utilized in competitive ELISAs of DiAcSpm (M assay) and DiAcSpd (D assay) as described below. 
RESULTS
Generation of Monoclonal Antibodies-The conjugation of AcSpm and N8-AcSpd to proteins using disuccinimidyl sub erate results in the formation of an acylamide linkage at the linker-monoacetylpolyamine junction, giving a struc ture that closely resembled the corresponding portion of diacetylpolyamines (10). We, therefore, chose these conju gates as antigens for raising antibodies against diacetyl polyamines.
Human urine usually contains some 30 and 10-fold molar excess of N1 and N8-AcSpd over DiAcSpm and DiAcSpd, respectively (7). Cross-reactions with these mono acetylpolyamines should be minimal if an anti-diacetyl polyamine antibody is to be used in an ELISA to determine the quantity of diacetylpolyamines in human urine without interference.
The supernatants from the 48 wells that gave a positive reaction with AcSpm-MSA in the first screening of 1 ,410 wells were examined further for DiAcSpm-specificity by comparing the ability of DiAcSpm and N1-AcSpd to com pete with AcSpm-MSA to bind the antibody in the superna tant fluid. Finally, MAb 9G9, which showed the highest preference for DiAcSpm over N1-AcSpd, was selected as an anti-DiAcSpm monoclonal antibody. Similarly, MAb 1D8 , which showed the highest preference for DiAcSpd over N8 AcSpd, was established as an anti-DiAcSpd monoclonal antibody. The latter antibody was chosen from 71 wells that Analytical Performance of the Assays- Figure  1 shows the competition by DiAcSpm and the cross-competition by Nl-AcSpd with HRP-AcSpm for binding to the anti DiAcSpm antibody in the M assay and by DiAcSpd and N8 AcSpd with HRP-AcSpm for binding to the anti-DiAcSpd antibody. The cross-reactivity of various polyamine species in the M and D assays, including these polyamines, is sum marized in Table I with the reactivities of DiAcSpm and DiAcSpd in the M and D assays, respectively, taken as 100%.
The within-run and between-run variations of the assays Table V . The results indicate that the excretion of diacetylpolyamines is generally stable with only minimal diurnal variation, ex cept for in the evening urine from a 5-year-old male (sub ject E). DISCUSSION We obtained monoclonal antibodies specifically recognizing DiAcSpm and DiAcSpd, and have used them to develop two ELISA systems to measure DiAcSpm and DiAcSpd . The assays are carried out in a 96-well microtiter plate coated with the appropriate antibody and are based on the compe tition between the diacetylpolyamine to be determined and a common enzyme-labeled antigen (AcSpm -HRP) for bind ing to the cognate monoclonal antibody on the plate . Under the conditions established in the present study, a compara ble amount of enzyme-labeled antigen was bound to plates coated with either antibody, and the binding was competed effectively at similar concentrations of the appropriate di acetylpolyamine, giving a comparable sensitivity of mea surement for both DiAcSpm and DiAcSpd. The use of a common enzyme-linked antigen makes it possible to mea sure the amount of two diacetylpolyamines in a very simi lar manner, which greatly simplifies the overall design of the procedure for the simultaneous determination of DiAcSpm and DiAcSpd.
As human urine contains various amounts of free and acetylated polyamines, the possibility that cross-reactions might significantly distort the diacetylpolyamine measure ments needs to be excluded. Overestimation of DiAcSpm due to cross-reaction with N1-AcSpd and of DiAcSpd due to Ns-AcSpd should be assessed most carefully, since other polyamine species either show only limited cross-reactivity or are relatively less abundant in urine. Human urine con tains, on average, 0.1, 2.7, 0.3, and 2.4 p.mol/g creatinine of DiAcSpm, Nl-AcSpd, DiAcSpd and N$-AcSpd , respectively (7). Based on the observed value for the cross-reactivity of N1-AcSpd with anti-DiAcSpm antibody and that of NIL AcSpd with anti-DiAcSpd antibody, overestimation due to N1-AcSpd and N8-AcSpd in healthy individuals would be approximately 7% in the M assay and 5% in the D assay . The former value is larger than the one expected in our previous ELISA for DiAcSpm that utilizes affinity-purified rabbit polyclonal antibodies (11), but is still within the range of precision of the present assay . The overestimation of DiAcSpd in the D assay is also within the range of preci sion of the assay. It should also be noted that the interfer ence due to monoacetylpolyamines would, in fact, be lower than the above estimate, since DiAcSpm and DiAcSpd lev els tend to increase more markedly than monoacetylpoly amines in tumor patients (8). Based on these considera tions we conclude that the proposed ELISA systems are specific enough for DiAcSpm and DiAcSpd to be used in clinical determinations of these diacetylpolyamines. The assay systems show good linearity over a wide range of DiAcSpm and DiAcSpd concentrations, and tolerate a considerable amount of NaCl and Urea. The recovery of exogenously added diacetylpolyamines was thus satisfac tory. Finally, the correlation between the values obtained by ELISA and HPLC was satisfactory, especially as to DiAcSpm. Altogether, the ELISA systems developed dur ing the course of this study are suitable for measuring uri nary diacetylpolyamines in that they are highly specific, reproducible, quantitative, and practically free from inter ference by other polyamine species as well as NaCl and Urea, which are abundant in urine. The ELISA systems were used to assess diurnal varia tions in diacetylpolyamine excretion in urine. It was shown that the excretion of diacetylpolyamines after normaliza tion as to the concentration of creatinine is stable over the period a day with only minimal diurnal variation. This vali dates the use of spot urine samples instead of pooled urine samples in estimating the daily excretion of diacetyl polyamines, which would help to simplify the protocol for clinical examination.
Samples from a 5-year-old male showed a decrease in the amount of creatinine-normalized diacetylpolyamine excretion toward evening, but it should be noted that even in this case, the secretion of diacetyl polyamines in urine samples collected in the morning did not deviate extensively from the daily average.
The daily excretions of DiAcSpm from subjects A to E were 0.099, 0.144, 0.246, 0.254, and 0.283 p,mol, and those of DiAcSpd were 0.352, 0.277, 0.287, 0.252, and 0.290 p.mol, respectively. It may be that children tend to excrete specifically more DiAcSpm than adults, with the excretion of DiAcSpd almost independent of age, but this should be examined more carefully in future studies. ita, K., Iwasaki, K., and Kawakita, M. (1995) Determination
